文献速递神经肿瘤神经重症

围手术期阿司匹林使用对择期脑肿瘤开颅术出血并发症的影响

Effect of perioperative aspirin use on hemorrhagic complications in elective craniotomy for brain tumors: results of a single-center, retrospective cohort study.
PubMed 文献 · J Neurosurg · 2019-04-05

该单中心回顾性队列纳入2007至2017年1291例择期颅内肿瘤手术患者,按围手术期阿司匹林(ASA)状态分为未用、停用和继续使用三组。结果显示三组出血和血栓栓塞并发症发生率均无显著差异,提示高心血管风险患者择期脑肿瘤手术可安全继续使用ASA。

要点

  • 继续使用ASA组与停用组的术中出血量无显著差异(220 ml对186 ml,p=0.183)。
  • 三组出血并发症(0.6%、0.9%、0.8%,p=0.921)和血栓栓塞并发症(1.3%、1.9%、0.8%,p=0.779)均无显著差异。
  • 男性(OR 5.9,95%CI 1.7-20.5,p=0.005)和深部-轴外-良性「颅底」肿瘤(OR 3.6,95%CI 1.3-9.7,p=0.011)是血栓栓塞并发症的独立预测因素。

核心结论

  • 在本队列中,围手术期使用ASA与颅内肿瘤手术后出血并发症发生率升高无关。
  • 高心血管风险患者择期脑肿瘤手术可安全继续使用ASA,以预防潜在危及生命的血栓栓塞并发症。
  • 作者认为仍需更大样本的随机临床试验以获得更高统计效能。

研究设计与样本

  • 单中心、回顾性队列研究,分析2007至2017年由单一术者实施的择期颅内肿瘤手术患者病历。
  • 共纳入1291例患者、1346次手术;未用ASA组1068例(1112次手术),停用ASA组104例(108次手术),继续ASA组119例(126次手术)。

主要发现

  • 未用ASA组患者平均年龄53.3岁,显著低于停用组(64.8岁)和继续组(64.0岁)(p<0.001);性别分布相似(p=0.272)。
  • 除深部肿瘤和神经鞘瘤在继续ASA组相对较少外,各组肿瘤部位和病理相似;各组切除程度(EOR)无差异。
  • 停用ASA组术中出血量186 ml,继续ASA组220 ml,两组无显著差异(p=0.183)。
  • 出血并发症发生率分别为0.6%、0.9%和0.8%(p=0.921),血栓栓塞并发症分别为1.3%、1.9%和0.8%(p=0.779),均无显著差异。
  • 多因素模型未发现出血并发症的显著预测因素;男性(OR 5.9,95%CI 1.7-20.5,p=0.005)和深部-轴外-良性「颅底」肿瘤(OR 3.6,95%CI 1.3-9.7,p=0.011)为血栓栓塞并发症的独立预测因素。

临床怎么用

  • 对高心血管风险患者,择期脑肿瘤开颅手术期间可考虑继续使用ASA以预防血栓栓塞并发症。
  • 决策时应结合患者心血管风险与肿瘤特征,尤其是深部-轴外-良性「颅底」肿瘤及男性患者的血栓栓塞风险。

局限性

  • 为单中心、单术者的回顾性队列研究,可能存在选择偏倚。
  • 各组样本量不均衡,继续和停用ASA组样本量较小。
  • 作者指出仍需更大样本的随机临床试验以取得更高统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In daily practice, neurosurgeons face increasing numbers of patients using aspirin (acetylsalicylic acid, ASA). While many of these patients discontinue ASA 7-10 days prior to elective intracranial surgery, there are limited data to support whether or not perioperative ASA use heightens the risk of hemorrhagic complications. In this study the authors retrospectively evaluated the safety of perioperative ASA use in patients undergoing craniotomy for brain tumors in the largest elective cranial surgery cohort reported to date. METHODS: The authors retrospectively analyzed the medical records of 1291 patients who underwent elective intracranial tumor surgery by a single surgeon from 2007 to 2017. The patients were divided into three groups based on their perioperative ASA status: 1) group 1, no ASA; 2) group 2, stopped ASA (low cardiovascular risk); and 3) group 3, continued ASA (high cardiovascular risk). Data collected included demographic information, perioperative ASA status, tumor characteristics, extent of resection (EOR), operative blood loss, any hemorrhagic and thromboembolic complications, and any other complications. RESULTS: A total of 1291 patients underwent 1346 operations. The no-ASA group included 1068 patients (1112 operations), the stopped-ASA group had 104 patients (108 operations), and the continued-ASA group had 119 patients (126 operations). The no-ASA patients were significantly younger (mean age 53.3 years) than those in the stopped- and continued-ASA groups (mean 64.8 and 64.0 years, respectively; p < 0.001). Sex distribution was similar across all groups (p = 0.272). Tumor locations and pathologies were also similar across the groups, except for deep tumors and schwannomas that were relatively less frequent in the continued-ASA group. There were no differences in the EOR between groups. Operative blood loss was not significantly different between the stopped- (186 ml) and continued- (220 ml) ASA groups (p = 0.183). Most importantly, neither hemorrhagic (0.6%, 0.9%, and 0.8%, respectively; p = 0.921) nor thromboembolic (1.3%, 1.9%, and 0.8%; p = 0.779) complication rates were significantly different between the groups, respectively. In addition, the multivariate model revealed no statistically significant predictor of hemorrhagic complications, whereas male sex (odds ratio [OR] 5.9, 95% confidence interval [CI] 1.7-20.5, p = 0.005) and deep-extraaxial-benign ("skull base") tumors (OR 3.6, 95% CI 1.3-9.7, p = 0.011) were found to be independent predictors of thromboembolic complications. CONCLUSIONS: In this cohort, perioperative ASA use was not associated with the increased rate of hemorrhagic complications following intracranial tumor surgery. In patients at high cardiovascular risk, ASA can safely be continued during elective brain tumor surgery to prevent potential life-threatening thromboembolic complications. Randomized clinical trials with larger sample sizes are warranted to achieve a greater statistical power.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hanalioglu S, Sahin B, Sahin OS, et al. Effect of perioperative aspirin use on hemorrhagic complications in elective craniotomy for brain tumors: results of a single-center, retrospective cohort study. J Neurosurg. 2019. PMID: 30952120. doi:10.3171/2018.12.JNS182483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。